Download PDF
Thromb Haemost 2019; 119(05): 705-715
DOI: 10.1055/s-0039-1681047
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Nonasaccharide Inhibits Intrinsic Factor Xase Complex by Binding to Factor IXa and Disrupting Factor IXa–Factor VIIIa Interactions

Chuang Xiao
1   State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
2   College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
3   School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, China
,
Longyan Zhao
1   State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
2   College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
4   School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China
,
Na Gao
1   State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
2   College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China
4   School of Pharmaceutical Sciences, South-Central University for Nationalities, Wuhan, China
,
Mingyi Wu
1   State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
,
Jinhua Zhao
1   State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
› Author Affiliations Funding This work was funded in part by the National Natural Science Foundation of China (31600649, 81773737, 81673330 and 81872774), Yunnan Provincial Science and Technology Department in China (2016FA050), and a grant from Youth Innovation Promotion Association (2017435), Chinese Academy of Sciences.
Further Information

Publication History

20 September 2018

17 January 2019

Publication Date:
21 March 2019 (online)

    Permissions and Reprints

Abstract

A nonasaccharide (FG9) derived from natural fucosylated glycosaminoglycan (FG) is identified as a selective intrinsic factor Xase complex (FIXa-FVIIIa-Ca2+-phospholipid, FXase) inhibitor that possesses potential inhibition of venous thrombus in rats and shows negligible bleeding risk. The mechanism and molecular target of the nonasaccharide for intrinsic FXase inhibition were systematically investigated and compared with low molecular weight heparin (LMWH). Our results showed that FG9 dose-dependently inhibited FX activation by intrinsic FXase complex in a noncompetitive inhibition pattern, where the apparent affinity for FG9 was approximately 1.8-fold higher than that for LMWH. FG9 displayed no inhibitory effect on the activity of FIXa/phospholipid, and did not affect the decay rate of FVIIIa activity. FG9 reduced the apparent affinity of FIXa for FVIIIa in a dose-dependent manner, and accelerated the decay of intrinsic FXase complex activity. FG9 bound to FIXa with high affinity and the FIXa binding sites of FG9 were overlapped with that of LMWH, and the ability of FG-derived oligosaccharides to bind FIXa required the minimum 9 degrees of polymerization. FG9 derivatives were prepared and their structures were confirmed by one-dimensional/two-dimensional nuclear magnetic resonance. Structure–activity relationship studies showed that carboxy reduction significantly weakened its anti-FXase activity and binding affinity to FIXa, while the effects of carboxyl ethyl esterification and deacetylation were relatively weaker. Overall, our results suggest that the nonasaccharide FG9 strongly inhibits intrinsic FXase complex activity via binding to FIXa and disrupting FIXa–FVIIIa interactions, and the free carboxyl groups of FG9 are required for its potent anti-FXase activity.

Keywords

nonasaccharide from fucosylated glycosaminoglycan - intrinsic factor Xase complex - factor IXa - anticoagulant

Authors' Contributions

C.X. performed research, analysed data and wrote the manuscript; L.Z. and N.G. performed research; M.W. revised the manuscript; and J.Z. designed the research, analysed data and revised the manuscript.


Supplementary Material

 

  • References

  • 1 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451 (7181): 914-918
    PubMedGoogle Scholar
  • 2 Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl): 257S-298S
    CrossrefPubMedGoogle Scholar
  • 3 Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121 (13) 1523-1532
    CrossrefPubMedGoogle Scholar
  • 4 Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004; 11 (09) 857-862
    CrossrefPubMedGoogle Scholar
  • 5 Olson ST, Richard B, Izaguirre G, Schedin-Weiss S, Gettins PG. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 2010; 92 (11) 1587-1596
    CrossrefPubMedGoogle Scholar
  • 6 Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003; 85 (1-2): 83-89
    CrossrefPubMedGoogle Scholar
  • 7 Colman RW. Are hemostasis and thrombosis two sides of the same coin?. J Exp Med 2006; 203 (03) 493-495
    CrossrefPubMedGoogle Scholar
  • 8 Renné T. Safe(r) anticoagulation. Blood 2010; 116 (22) 4390-4391
    CrossrefPubMedGoogle Scholar
  • 9 Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014; 111 (04) 570-574
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88 (09) 3432-3445
    CrossrefPubMedGoogle Scholar
  • 11 Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277 (21) 18322-18333
    CrossrefPubMedGoogle Scholar
  • 12 Zhao L, Wu M, Xiao C. , et al. Discovery of an intrinsic tenase complex inhibitor: pure nonasaccharide from fucosylated glycosaminoglycan. Proc Natl Acad Sci U S A 2015; 112 (27) 8284-8289
    CrossrefPubMedGoogle Scholar
  • 13 Pomin VH. Holothurian fucosylated chondroitin sulfate. Mar Drugs 2014; 12 (01) 232-254
    CrossrefPubMedGoogle Scholar
  • 14 Nagase H, Enjyoji K, Minamiguchi K. , et al. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995; 85 (06) 1527-1534
    CrossrefPubMedGoogle Scholar
  • 15 Nagase H, Enjyoji K, Shima M. , et al. Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. J Biochem 1996; 119 (01) 63-69
    CrossrefPubMedGoogle Scholar
  • 16 Glauser BF, Pereira MS, Monteiro RQ, Mourão PA. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thromb Haemost 2008; 100 (03) 420-428
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Wu M, Wen D, Gao N. , et al. Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase. Eur J Med Chem 2015; 92: 257-269
    CrossrefPubMedGoogle Scholar
  • 18 Li JZ, Lian EC. Aggregation of human platelets by acidic mucopolysaccharide extracted from Stichopus japonicus Selenka. Thromb Haemost 1988; 59 (03) 435-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Fonseca RJ, Oliveira SN, Pomin VH, Mecawi AS, Araujo IG, Mourão PA. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010; 103 (05) 994-1004
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kitazato K, Kitazato KT, Nagase H, Minamiguchi K. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats. Thromb Res 1996; 84 (02) 111-120
    CrossrefPubMedGoogle Scholar
  • 21 Kitazato K, Kitazato KT, Sasaki E, Minamiguchi K, Nagase H. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation. Thromb Res 2003; 112 (1-2): 83-91
    CrossrefPubMedGoogle Scholar
  • 22 Gao N, Lu F, Xiao C. , et al. β-Eliminative depolymerization of the fucosylated chondroitin sulfate and anticoagulant activities of resulting fragments. Carbohydr Polym 2015; 127: 427-437
    CrossrefPubMedGoogle Scholar
  • 23 Buyue Y, Sheehan JP. Fucosylated chondroitin sulfate inhibits plasma thrombin generation via targeting of the factor IXa heparin-binding exosite. Blood 2009; 114 (14) 3092-3100
    CrossrefPubMedGoogle Scholar
  • 24 Sheehan JP, Walke EN. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood 2006; 107 (10) 3876-3882
    CrossrefPubMedGoogle Scholar
  • 25 Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD. A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977; 16 (12) 2806-2810
    CrossrefPubMedGoogle Scholar
  • 26 Bloom JW, Nesheim ME, Mann KG. Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979; 18 (20) 4419-4425
    CrossrefPubMedGoogle Scholar
  • 27 Morrison WRA. Fast, simple and reliable method for the microdetermination of phosphorus in biological materials. Anal Biochem 1964; 7: 218-224
    CrossrefPubMedGoogle Scholar
  • 28 Wu M, Xu S, Zhao J, Kang H, Ding H. Preparation and characterization of molecular weight fractions of glycosaminoglycan from sea cucumber Thelenata ananas using free radical depolymerization. Carbohydr Res 2010; 345 (05) 649-655
    CrossrefPubMedGoogle Scholar
  • 29 Zhao L, Lai S, Huang R. , et al. Structure and anticoagulant activity of fucosylated glycosaminoglycan degraded by deaminative cleavage. Carbohydr Polym 2013; 98 (02) 1514-1523
    CrossrefPubMedGoogle Scholar
  • 30 Barrow RT, Parker ET, Krishnaswamy S, Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269 (43) 26796-26800
    CrossrefPubMedGoogle Scholar
  • 31 Sheehan JP, Phan TM. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001; 40 (16) 4980-4989
    CrossrefPubMedGoogle Scholar
  • 32 Sheehan JP, Kobbervig CE, Kirkpatrick HM. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry 2003; 42 (38) 11316-11325
    CrossrefPubMedGoogle Scholar
  • 33 Yuan QP, Walke EN, Sheehan JP. The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. Biochemistry 2005; 44 (09) 3615-3625
    CrossrefPubMedGoogle Scholar
  • 34 Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem 1996; 271 (11) 6027-6032
    CrossrefPubMedGoogle Scholar
  • 35 Li B, Suwan J, Martin JG. , et al. Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol 2009; 78 (03) 292-300
    CrossrefPubMedGoogle Scholar
  • 36 Cochran S, Li CP, Ferro V. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconj J 2009; 26 (05) 577-587
    CrossrefPubMedGoogle Scholar
  • 37 Xiao C, Lian W, Zhou L. , et al. Interactions between depolymerized fucosylated glycosaminoglycan and coagulation proteases or inhibitors. Thromb Res 2016; 146: 59-68
    CrossrefPubMedGoogle Scholar
  • 38 Figuera-Losada M, LoGrasso PV. Enzyme kinetics and interaction studies for human JNK1β1 and substrates activating transcription factor 2 (ATF2) and c-Jun N-terminal kinase (c-Jun). J Biol Chem 2012; 287 (16) 13291-13302
    CrossrefPubMedGoogle Scholar
  • 39 Lian W, Wu M, Huang N. , et al. Anti-HIV-1 activity and structure-activity-relationship study of a fucosylated glycosaminoglycan from an echinoderm by targeting the conserved CD4 induced epitope. Biochim Biophys Acta 2013; 1830 (10) 4681-4691
    CrossrefPubMedGoogle Scholar
  • 40 Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265 (03) 1688-1692
    CrossrefPubMedGoogle Scholar
  • 41 Santos GR, Glauser BF, Parreiras LA, Vilanova E, Mourão PA. Distinct structures of the α-fucose branches in fucosylated chondroitin sulfates do not affect their anticoagulant activity. Glycobiology 2015; 25 (10) 1043-1052
    CrossrefPubMedGoogle Scholar
  • 42 Yang L, Manithody C, Rezaie AR. Localization of the heparin binding exosite of factor IXa. J Biol Chem 2002; 277 (52) 50756-50760
    CrossrefPubMedGoogle Scholar
  • 43 Griffiths AE, Rydkin I, Fay PJ. Factor VIIIa A2 subunit shows a high affinity interaction with factor IXa: contribution of A2 subunit residues 707-714 to the interaction with factor IXa. J Biol Chem 2013; 288 (21) 15057-15064
    CrossrefPubMedGoogle Scholar
  • 44 Mourão PA, Pereira MS, Pavão MS. , et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem 1996; 271 (39) 23973-23984
    CrossrefPubMedGoogle Scholar
  • 45 Zhang X, Liu H, Lin L. , et al. Synthesis of fucosylated chondroitin sulfate nonasaccharide as a novel anticoagulant targeting intrinsic factor Xase complex. Angew Chem Int Ed Engl 2018; 57 (39) 12880-12885
    CrossrefPubMedGoogle Scholar
  • 46 Petitou M, van Boeckel CA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem Int Ed Engl 2004; 43 (24) 3118-3133
    CrossrefPubMedGoogle Scholar